We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French-based Neovacs has signed a commercial licence option agreement with BioSense Global for the development and commercial rights of IFNα Kinoid vaccine to treat lupus and dermatomyositis in China.